Search research articles
Contact Us
Filters
Showing results (31-40 of 79) with videos related to
Page
of 8
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 1, 2013
Impact of cabazitaxel on 2-year survival and palliation of tumour-related pain in men with metastatic castration-resistant prostate cancer treated in the TROPIC trial
A Bahl, S Oudard, B Tombal, et al.
BJU International
|
June 26, 2003
Improved prognosis of patients with intermediate- and poor-risk nonseminomatous germ cell tumours by optimizing combined treatment
G Pentheroudakis, J S De Bono, S B Kaye, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 21, 2019
A decade of clinical development of PARP inhibitors in perspective
J Mateo, C J Lord, V Serra, et al.
British Journal of Cancer
|
November 15, 2007
A phase Ib study of pertuzumab, a recombinant humanised antibody to HER2, and docetaxel in patients with advanced solid tumours
G Attard, J Kitzen, S P Blagden, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 13, 2012
Defining the risk of toxicity in phase I oncology trials of novel molecularly targeted agents: a single centre experience
L R Molife, S Alam, D Olmos, et al.
Cancer Chemotherapy and Pharmacology
|
September 13, 2014
A first-in-human study of the anti-α5β1 integrin monoclonal antibody PF-04605412 administered intravenously to patients with advanced solid tumors
J Mateo, J Berlin, J S de Bono, et al.
British Journal of Cancer
|
July 2, 2014
Validation and utilisation of high-coverage next-generation sequencing to deliver the pharmacological audit trail
M Ong, S Carreira, J Goodall, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 2, 2011
Randomised phase II study of siltuximab (CNTO 328), an anti-IL-6 monoclonal antibody, in combination with mitoxantrone/prednisone versus mitoxantrone/prednisone alone in metastatic castration-resistant prostate cancer
K Fizazi, J S De Bono, A Flechon, et al.
Cancer Chemotherapy and Pharmacology
|
August 14, 2010
Pharmacokinetic and pharmacodynamic properties of an oral formulation of the histone deacetylase inhibitor Belinostat (PXD101)
N L Steele, J A Plumb, L Vidal, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 27, 2006
A phase I study of intravenous TZT-1027 administered on day 1 and day 8 of a three-weekly cycle in combination with carboplatin given on day 1 alone in patients with advanced solid tumours
A Greystoke, S Blagden, A L Thomas, et al.
Page
of 8
Search research articles
Search
Showing results (31-40 of 79) with videos related to
Sort By:
Page
of 8
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 1, 2013
Impact of cabazitaxel on 2-year survival and palliation of tumour-related pain in men with metastatic castration-resistant prostate cancer treated in the TROPIC trial
A Bahl, S Oudard, B Tombal, et al.
BJU International
|
June 26, 2003
Improved prognosis of patients with intermediate- and poor-risk nonseminomatous germ cell tumours by optimizing combined treatment
G Pentheroudakis, J S De Bono, S B Kaye, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 21, 2019
A decade of clinical development of PARP inhibitors in perspective
J Mateo, C J Lord, V Serra, et al.
British Journal of Cancer
|
November 15, 2007
A phase Ib study of pertuzumab, a recombinant humanised antibody to HER2, and docetaxel in patients with advanced solid tumours
G Attard, J Kitzen, S P Blagden, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 13, 2012
Defining the risk of toxicity in phase I oncology trials of novel molecularly targeted agents: a single centre experience
L R Molife, S Alam, D Olmos, et al.
Cancer Chemotherapy and Pharmacology
|
September 13, 2014
A first-in-human study of the anti-α5β1 integrin monoclonal antibody PF-04605412 administered intravenously to patients with advanced solid tumors
J Mateo, J Berlin, J S de Bono, et al.
British Journal of Cancer
|
July 2, 2014
Validation and utilisation of high-coverage next-generation sequencing to deliver the pharmacological audit trail
M Ong, S Carreira, J Goodall, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 2, 2011
Randomised phase II study of siltuximab (CNTO 328), an anti-IL-6 monoclonal antibody, in combination with mitoxantrone/prednisone versus mitoxantrone/prednisone alone in metastatic castration-resistant prostate cancer
K Fizazi, J S De Bono, A Flechon, et al.
Cancer Chemotherapy and Pharmacology
|
August 14, 2010
Pharmacokinetic and pharmacodynamic properties of an oral formulation of the histone deacetylase inhibitor Belinostat (PXD101)
N L Steele, J A Plumb, L Vidal, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 27, 2006
A phase I study of intravenous TZT-1027 administered on day 1 and day 8 of a three-weekly cycle in combination with carboplatin given on day 1 alone in patients with advanced solid tumours
A Greystoke, S Blagden, A L Thomas, et al.
Page
of 8